In this article, we review the two major transcriptional factors, Nrf2 and HIF, and agents targeting them as promising therapies for CKD and reconsider the mechanism of RAS inhibitors, focusing on the transcription factor KLF4 based on our recent work. Here, NFE2L2 is linked to chronic kidney disease.